MA53258A - Composés pour le traitement de la maladie d'alzheimer - Google Patents
Composés pour le traitement de la maladie d'alzheimerInfo
- Publication number
- MA53258A MA53258A MA053258A MA53258A MA53258A MA 53258 A MA53258 A MA 53258A MA 053258 A MA053258 A MA 053258A MA 53258 A MA53258 A MA 53258A MA 53258 A MA53258 A MA 53258A
- Authority
- MA
- Morocco
- Prior art keywords
- alzheimer
- disease
- compounds
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/29—Mineral substances, e.g. mineral oils or clays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305245 | 2018-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53258A true MA53258A (fr) | 2021-08-04 |
Family
ID=61691894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053258A MA53258A (fr) | 2018-03-07 | 2019-03-07 | Composés pour le traitement de la maladie d'alzheimer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210052589A1 (fr) |
| EP (1) | EP3761987A1 (fr) |
| JP (1) | JP2021517124A (fr) |
| KR (1) | KR20210005848A (fr) |
| CN (1) | CN112236145A (fr) |
| AU (1) | AU2019232139A1 (fr) |
| BR (1) | BR112020018164A2 (fr) |
| CA (1) | CA3093212A1 (fr) |
| MA (1) | MA53258A (fr) |
| MX (1) | MX2020009334A (fr) |
| RU (1) | RU2020132761A (fr) |
| WO (1) | WO2019170834A1 (fr) |
| ZA (1) | ZA202006126B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR2023011879A2 (tr) * | 2023-09-25 | 2024-01-22 | T C Ueskuedar Ueniversitesi | Alzheimer hastalığının tedavisinde kullanılmak üzere bir formülasyon. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033703A2 (fr) * | 1995-04-25 | 1996-10-31 | Oridigm Corporation | Regulation de la s-adenosyl methionine des voies metaboliques et application au diagnostic et a la therapie |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| WO2002002190A2 (fr) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention et traitement de maladies degeneratives par le glutathion et des enzymes de detoxification de phase ii |
| GB201417163D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| ES2800917T3 (es) * | 2016-08-30 | 2021-01-05 | Amabiotics | Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial |
-
2019
- 2019-03-07 EP EP19714549.3A patent/EP3761987A1/fr not_active Withdrawn
- 2019-03-07 JP JP2020546461A patent/JP2021517124A/ja active Pending
- 2019-03-07 CA CA3093212A patent/CA3093212A1/fr active Pending
- 2019-03-07 MA MA053258A patent/MA53258A/fr unknown
- 2019-03-07 RU RU2020132761A patent/RU2020132761A/ru unknown
- 2019-03-07 US US16/977,979 patent/US20210052589A1/en active Pending
- 2019-03-07 KR KR1020207028162A patent/KR20210005848A/ko active Pending
- 2019-03-07 CN CN201980027292.9A patent/CN112236145A/zh active Pending
- 2019-03-07 WO PCT/EP2019/055780 patent/WO2019170834A1/fr not_active Ceased
- 2019-03-07 MX MX2020009334A patent/MX2020009334A/es unknown
- 2019-03-07 AU AU2019232139A patent/AU2019232139A1/en not_active Abandoned
- 2019-03-07 BR BR112020018164-1A patent/BR112020018164A2/pt not_active IP Right Cessation
-
2020
- 2020-10-02 ZA ZA2020/06126A patent/ZA202006126B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020009334A (es) | 2021-02-15 |
| CA3093212A1 (fr) | 2019-09-12 |
| RU2020132761A (ru) | 2022-04-07 |
| WO2019170834A1 (fr) | 2019-09-12 |
| EP3761987A1 (fr) | 2021-01-13 |
| CN112236145A (zh) | 2021-01-15 |
| US20210052589A1 (en) | 2021-02-25 |
| AU2019232139A1 (en) | 2020-10-08 |
| KR20210005848A (ko) | 2021-01-15 |
| JP2021517124A (ja) | 2021-07-15 |
| BR112020018164A2 (pt) | 2021-02-02 |
| ZA202006126B (en) | 2023-03-29 |
| RU2020132761A3 (fr) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| EP3728271A4 (fr) | Composés macrocycliques pour le traitement de maladie | |
| EP3675859A4 (fr) | Composés, compositions et méthodes pour le traitement d'une maladie | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3820537A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| EP3856478A4 (fr) | Formulations pour le traitement de la maladie de l'oeil sec | |
| EP3737361A4 (fr) | Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3762505A4 (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3402533A4 (fr) | Méthodes et compositions pour le traitement d'une maladie neurologique | |
| EP3528852A4 (fr) | Méthodes et compositions pour le traitement de la maladie de fabry | |
| EP3504204A4 (fr) | Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie | |
| EP3432892A4 (fr) | Antagonistes dérivés du mannose de fimh utiles pour le traitement d'une maladie | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
| EP3846821A4 (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
| EP3796980A4 (fr) | Thérapie génique pour la maladie d'alzheimer | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| MA53739A (fr) | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés | |
| MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique | |
| EP4297868A4 (fr) | Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer | |
| EP3823616A4 (fr) | Utilisation de promédicaments à base de riluzole pour traiter la maladie d'alzheimer | |
| EP3730144A4 (fr) | Agent pour le traitement d'une maladie du système nerveux |